United States Antimony (UAMY) Is Down 16.4% After Defense-Funded Expansion Push Amid Weak Q1 Results

• In May 2026, United States Antimony Corporation reported first-quarter 2026 sales of US$6.78 million, down from US$7.00 million a year earlier, and a net loss of US$11.29 million (US$0.08 loss per share) compared with prior-year net income.
• At the same time, the company highlighted sizable U.S. government grants, a US$245.00 million Defense Logistics Agency contract, and expansion into additional critical minerals, underscoring an aggressive build-out of its processing and mining footprint despite weak quarterly results.
• We’ll examine how the sizeable federal grants and defense-linked contracts reshape United States Antimony’s investment narrative after this weak quarter.

Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

United States Antimony Investment Narrative Recap

To own United States Antimony today, you need to believe the company can convert its U.S. government support and critical-minerals footprint into sustainable, profitable volumes. The latest quarter’s US$11.29 million loss and weaker sales sharpen the focus on near term execution under federal contracts, especially the timing of Defense Logistics Agency shipments, while also highlighting the key risk that heavy expansion and dilution may outpace the company’s ability to generate matching cash flow.

The most relevant recent announcement here is management’s reaffirmation of roughly US$125 million in 2026 gross revenue guidance despite the weak first quarter. That target rests heavily on defense and federal-grant supported projects, including the US$245.00 million DLA award and new processing capacity such as the Idaho plant, making contract delivery schedules and permitting progress central to whether today’s expansion story translates into tomorrow’s reported results.

Yet investors should also weigh the risk that heavy reliance on a few large defense contracts could quickly cut both ways if...

Read the full narrative on United States Antimony (it's free!)

United States Antimony's narrative projects $327.7 million revenue and $84.7 million earnings by 2029.

Uncover how United States Antimony's forecasts yield a $12.67 fair value, a 52% upside to its current price.

Exploring Other Perspectives

Before this setback, the most optimistic analysts were penciling in about US$333 million of revenue and US$71 million of earnings by 2029, so if you lean on that far more upbeat view of contract driven growth and margin expansion, this disappointing quarter is exactly the kind of event that could force you to revisit how confident you really are in those assumptions.

Explore 18 other fair value estimates on United States Antimony - why the stock might be worth over 4x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your United States Antimony research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free United States Antimony research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate United States Antimony's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Find 51 companies with promising cash flow potential yet trading below their fair value.
• Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com